489 related articles for article (PubMed ID: 11803074)
1. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E
Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074
[TBL] [Abstract][Full Text] [Related]
2. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
[TBL] [Abstract][Full Text] [Related]
3. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
4. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
[TBL] [Abstract][Full Text] [Related]
6. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
[TBL] [Abstract][Full Text] [Related]
7. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
[TBL] [Abstract][Full Text] [Related]
8. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
Liu YB; Hu Y; Deng XY; Wang ZG; Sun X; Lu PS; Guo HX; Tang FY; Zhou MH
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):593-597. PubMed ID: 28693082
[No Abstract] [Full Text] [Related]
9. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
10. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
[TBL] [Abstract][Full Text] [Related]
11. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
12. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
16. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
17. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
[TBL] [Abstract][Full Text] [Related]
18. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
Haralambieva IH; Ovsyannikova IG; Kennedy RB; Goergen KM; Grill DE; Chen MH; Hao L; Icenogle J; Poland GA
Vaccine; 2020 Jan; 38(5):1249-1257. PubMed ID: 31732325
[TBL] [Abstract][Full Text] [Related]
19. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
McLean HQ; Fiebelkorn AP; Ogee-Nwankwo A; Hao L; Coleman LA; Adebayo A; Icenogle JP
Vaccine; 2018 Sep; 36(38):5732-5737. PubMed ID: 30107992
[TBL] [Abstract][Full Text] [Related]
20. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.
Saffar H; Khalifeloo M; Saffar MJ; Abdollahi A; Parsaei MR; Ghorbani GR; Salarvand S; Aarabi M
BMC Infect Dis; 2021 Mar; 21(1):305. PubMed ID: 33765968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
